Finding and evaluating branded and generic biopharmaceutical market entry opportunities
Instructor:
Yali Friedman
Product ID: 706331
- Duration: 120 Min
Why Should You Attend:
For branded companies, finding ways to strengthen patent protection can be worth billions of dollars.
For generic companies, being first-to-market can yield competitive advantages that last for years.
Whether your specialty is in branded drugs, generic drugs, or elsewhere in the drug discovery/delivery value chain, this webinar will teach you how to anticipate and prepare for revenue-changing events.
When drug patents expire or are invalidated billions of dollars in value can shift from branded to generic drug companies. Innovative pharmaceutical companies are challenged to prioritize high-value launches and find the best ways to protect their drugs. Generic companies seek to find right-sized market-entry opportunities and to compete with other potential generic entrants. And, 505(b)(2) hybrid drugs add complexity by blurring the lines between branded and generic drugs.
This webinar will lay out the competitive landscape for branded and generic drug launches, and strategies to find and evaluate opportunities.
Areas Covered in the Webinar:
- Be a value-added partner
- Anticipate generic entry so you can prepare for changes in demand
- Find and evaluate generic entry opportunities
- Learn factors influencing generic entry decisions
- Learn why generic first-entrants enjoy long-term market dominance
- Find opportunities to launch 505(b)(2) hybrid drugs
- Use authorized generics to your advantage
- Find out when a branded generic strategy makes sense
- Find low-competition generic opportunities
Who Will Benefit:
- Generally, portfolio managers at branded and generic drug companies. They may have ‘portfolio’, ‘insights’ or ‘analytics/analyst’ in their job titles.
- Also, formulary managers at PBMs and health care plans.
- And, business development functions at any company that supplies raw chemicals or distributes finished drug products.
Free Materials:
- eBook of Make Better Decisions – Finding and Evaluating Generic and Branded Drug Market Entry Opportunities
- Articles
Yali Friedman
Founder, DrugPatentWatch.com
Yali Friedman, Ph.D. has more than 20 years’ experience providing business intelligence to life science companies. He was recently named one of the 100 most influential people in biotechnology by Scientific American. He is also author of the MBA-level textbook Building Biotechnology and publisher of the Journal of Commercial Biotechnology.
Refund Policy
Our refund policy is governed by individual products and services refund policy mentioned against each of offerings. However in absence of specific refund policy of an offering below refund policy will be effective.
Registrants may cancel up to two working days prior to the course start date and will receive a letter of credit to be used towards a future course up to one year from date of issuance. ComplianceOnline would process/provide refund if the Live Webinar has been cancelled. The attendee could choose between the recorded version of the webinar or refund for any cancelled webinar. Refunds will not be given to participants who do not show up for the webinar. On-Demand Recordings can be requested in exchange. Webinar may be cancelled due to lack of enrolment or unavoidable factors. Registrants will be notified 24hours in advance if a cancellation occurs. Substitutions can happen any time. On-Demand Recording purchases will not be refunded as it is available for immediate streaming. However if you are not able to view the webinar or you have any concern about the content of the webinar please contact us at below email or by call mentioning your feedback for resolution of the matter. We respect feedback/opinions of our customers which enables us to improve our products and services. To contact us please email [email protected] call +1-888-717-2436 (Toll Free).
